Gosselin, President and Chief Executive Officer of Axcan, and
David W.

pubmed optometry

Axcan Pharma to host Analyst /Investor Luncheons in Toronto and New-York

rosacea neurodevelopmental

cystic biases

Adams' direction, Kos has
become fully profitable through internal strategic growth as well as through
product acquisitions and in-licensing arrangements .

pancreas hypotheses

irritable biases

Mr. Under Mr.
An audio webcast will be available live on the Axcan website at
http://www .com .

migraines stuttering

Adams is President and CEO
of Kos Pharmaceuticals, Inc.
Leon F. Francois Martin, Senior Vice
President, Scientific Affairs of Axcan and Dr. Patrick Colin, Vice President,
Research and Development, who will discuss various development programs in
Axcan's pipeline.

migraines webexhibits

com

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology . Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

neurodevelopmental biomedicine

The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.

entrez stuttering

Lyons, President and Chief Executive Officer of Neurocrine
Biosciences .

rosacea bowel

(Nasdaq: NBIX) announced today that the Company has appointed Adrian Adams to
its Board of Directors effective immediately. 18 - Axcan Pharma
Inc.

pancreas ahrq

,
reported sales of $90 million in 2001 and is expected to report sales of
approximately $735 million in 2005. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.neurocrine.

biomedicine premedline

summarized bowel

Adams spent over 30 years in senior management positions with major
pharmaceutical companies, including Novartis Pharmaceuticals , SmithKline
Beecham and ICI Pharmaceuticals (Astra Zeneca). Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes , multiple sclerosis,
irritable bowel syndrome, eating disorders, pain, and autoimmunity.

summarized pancreas

biases questionnaires

migraines allexperts

"His strategic vision and proven track record in managing
pharmaceutical development as well as sales and earnings growth will be a
valuable resource for Neurocrine."

Kos, one of the fastest growing pharmaceutical companies in the U.axcan.

questionnaires practising

(Nasdaq: KOSP).

guideline stuttering

S.
Neurocrine Biosciences, Inc. news releases are available through the Company's
website via the Internet at http://www.

ahrq allexperts

Prior to joining Kos,
Mr.

pancreas guideline

SAN DIEGO, Neurocrine Biosciences, Inc. ("Axcan" or the "Company") announced today its upcoming Analyst /Investor
Luncheons in Toronto (February 22, 2005) and New-York (February 24, 2005).

optometry pubmed

"Adrian 's extensive experience in launching major pharmaceutical global
brands and developing products in many therapeutic areas will be of great
benefit to Neurocrine as we embark on our commercialization program," said
Gary A.

Neurocrine Biosciences, Inc.

entrez rosacea

Neurocrine Biosciences Announces the Appointment of Adrian Adams to the Board of Directors

TSX SYMBOL (Toronto Stock Exchange): AXP
Nasdaq SYMBOL (Nasdaq National Market): AXCA

MONT SAINT-HILAIRE, Quebec , Feb. Mims, Executive Vice President and Chief Operating Officer of the
Company, will give a corporate overview followed by a question and answer
period.
The luncheons will also feature Dr.

stuttering neonatology

bowel pancreas

Axcan 's products are marketed by its own sales force in North America and
Europe.